Analyst
UBS
Equibles does not estimate personal net worth.
Colin Bristow is recorded as Analyst at UBS. Earlier roles on record: Board Member at Spectral AI, Inc. (MDAI) until January 5, 2026. Spectral AI, Inc. reported in an 8-K filed January 6, 2026 that Colin Bristow resigned as director on the Board of Directors of the Company, effective January 5, 2026. Colin Bristow has spoken on 3 earnings calls across 3 companies, most recently for Gilead Sciences, Inc. on February 6, 2024. Those appearances were for Gilead Sciences, Inc. (GILD), ELI LILLY & Co (LLY) and Sarepta Therapeutics, Inc. (SRPT). The companies whose calls Colin Bristow spoke on are classified in the Healthcare sector.
“On January 5, 2026, Colin Bristow tendered his resignation as a director on the Board of Directors of the Company, with such resignation becoming effective immediately.”
“Afternoon, and thanks for pleasing me in. Can you hear me? Yes, we can hear you.”
“So, it looks like the net price dropped to gain in 3Q to 4Q. Can you just walk us through what specifically drove this, and just update us on how you expect this to trend over the course of the year?”
“So, first one, I understand the agency hasn’t fully blessed the faster market, but in terms of the willingness to accept this 8 to 10 patients is sufficient evidence of comparability between the commercial and clinical product.”
UBS
Analyst
Source not stated
Start not stated–2026-01-05
Drug Manufacturers - General · Healthcare
LLY
Drug Manufacturers - General · Healthcare
